NCT01818661 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech
| NCT ID | NCT01818661 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mayo Clinic |
| Condition | PPA |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2018-07-01 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2018-07-01 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).
Eligibility Criteria
Inclusion Criteria: * We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic Exclusion Criteria: * Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded. * Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan. * Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy). * Subjects will also be excluded if they do not have an informant, or do not consent to research.
Contact & Investigator
Jennifer Whitwell, PhD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT01818661 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PPA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT01818661 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT01818661 currently recruiting?
Yes, NCT01818661 is actively recruiting participants. Contact the research team at boland.sarah@mayo.edu for enrollment information.
Where is the NCT01818661 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT01818661 clinical trial?
NCT01818661 is sponsored by Mayo Clinic. The principal investigator is Jennifer Whitwell, PhD at Mayo Clinic. The trial plans to enroll 50 participants.